ClinicalTrials.gov term: Myelodysplastic-Myeloproliferative Diseases
MDS/MPN Overlap clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
12 trials changed in the last 30 days: 2 stopped, 3 with notable changes, 7 with minor changes only.
- Stopped: Two Step Haplo With Radiation Conditioning Recruitment suspended
- Notable: APTBCy · Optimization of Post-transplantation Benadamustine and Cyclophosphamide · High-risk Myeloid Malignancies and a Partially Mismatched Donor Primary and study completion pushed from Dec 10, 2026 to Dec 10, 2027
- Notable: Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood · Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Primary and study completion pushed from Dec 31, 2030 to Dec 31, 2032
- Minor: Clofarabine and Melphalan Before Donor Stem Cell Transplant · Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia Study completion pushed from Sep 21, 2026 to Aug 23, 2027
- Minor: Ropeginterferon Alfa-2b · Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Primary completion pushed from Sep 30, 2031 to Jan 30, 2032
- Stopped: Hu8F4 · Advanced Hematologic Malignancies Trial terminated
- Minor: Trametinib · Relapsed or Refractory Juvenile Myelomonocytic Leukemia Study completion pushed from Oct 3, 2026 to Oct 14, 2027
- Minor: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens · Hematologic Malignancies Start date changed from estimate of Nov 4, 2026 to Oct 28, 2026
- Minor: Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at · Hemoblastosis Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2023); last known: Active, Not Recruiting
- Notable: Therapeutic RSK1 Targeting in Myeloid Malignancies Enrollment increased: 18 → 30 participants
- Minor: MYELOMATCH · Screening Study to Assign · Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Trial sites expanded: 354 → 358 locations
- Minor: CONCERTO · Cobimetinib in Newly Diagnosed or HMA-treated CMML · RAS Pathway Mutations Study completion pushed from Aug 2026 to Oct 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-11-03 | NCT07914556 Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers | Mabwell (Shanghai) Bioscience Co., Ltd. new | Phase 1 |
Active trials by phase
| Early Phase 1 | 3 | |
| Phase 1 | 34 | |
| Phase 1/2 | 27 | |
| Phase 2 | 56 | |
| Phase 2/3 | 2 | |
| Phase 3 | 4 |
Not charted: 27 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
M.D. Anderson Cancer Center (19) · National Cancer Institute (NCI) (11) · Fred Hutchinson Cancer Center (9) · City of Hope Medical Center (8) · Center for International Blood and Marrow Transplant Research (3) · Mayo Clinic (3) · Peking University People's Hospital (3) · St. Jude Children's Research Hospital (3) · Centre Hospitalier Universitaire de Nice (2) · Dana-Farber Cancer Institute (2)
Get alerts when MDS/MPN Overlap trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.